Steven Allen, MD

Associate Investigator, The Feinstein Institute for Medical Research

Associate Chief, Division of Hematology, North Shore University Hospital & LIJ Medical Center

Professor of Medicine, Hofstra Northwell School Of Medicine

Phone: (516) 734-8959

About the Investigator
Dr. Allen is Associate Chief of Hematology, Division of Medical Oncology and Hematology at North Shore University Hospital/LIJ Medical Center. His clinical practice is dedicated to the treatment of hematologic malignancies, including leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, benign hematologic disorders and coagulation.

Dr. Allen is board certified in internal medicine and hematology/medical oncology. He received his medical degree from the Johns Hopkins School of Medicine, completed his residency in Internal Medicine and served as a Hematology/Medical Oncology Fellow at New York Hospital.

Dr. Allen is Chair of the American Society of Hematology’s Committee on Practice, a member of the Society’s Executive Committee, and serves on its Task Force on Quality Measures, for which he received its Outstanding Service Award. Dr. Allen is Co-Chair of the AMA’s Physician Consortium for Performance Improvement – Hematology Work Group and an active member of numerous other medical boards and associations. He has authored or co-authored more than 100 original research papers and reviews and is Professor of Medicine at the Hofstra Northwell School of Medicine.

Research Focus
Through more than 25 years experience focusing on the treatment of hematologic malignancies, Dr. Allen has the expertise, leadership and motivation necessary to successfully carry out the proposed work. He has served as Principal Investigator or Co-Investigator for many clinical trials involving the treatment of patients with myelodysplastic syndrome and leukemia including studies involving close collaboration between the clinician and basic science laboratory. This has been done with great success in chronic lymphocytic leukemia where serial samples over time have been obtained and studied in collaboration with basic science laboratories.

Dr. Allen has been an active member of the National Cancer Institute sponsored Community Clinical Oncology Program participating in multiple Cooperative group clinical trials for patients with hematologic malignancies. He has successfully administered the projects (e.g. staffing, research protections, budget), collaborated with other researchers and produced over 100 peer-reviewed publications based upon these projects.

As a result of his previous experience, Dr. Allen is aware of the requirements to successfully undertake a clinical trial following good clinical practice guidelines. He has a demonstrated record of successful and productive myeloproliferative disease research in this patient population.

The City College, New York, NY
Degree: BS
Field of Study: Chemistry

Johns Hopkins School of Medicine, Baltimore MD
Degree: MD
Field of Study: Medicine

Honors and Awards
2016 Excellence in Research Award, Feinstein Institute for Medical Research
2012-Present “New York Super Doctors”
2011 “America’s Most Compassionate Doctors”
2010-Present “America’s Top Doctors for Cancer”, Castle Connolly Guide
2009-Present “Patients’ Choice” Award
2007-Present “Best Doctors in America”
2007 “Guide to America’s Top Oncologists”, Consumers’ Research Council of America
2006 Outstanding Service Award, American Society of Hematology
2005 Champion of Advocacy Award, American Society of Hematology
2004-Present “Best Doctors”, New York Magazine
2003-Present “Guide to America’s Top Physicians”, Consumers’ Research Council of America
1993-Present “Top Doctors: New York Metro Area”, Castle Connolly Guide
1985 Fellow, American College of Physicians
1984-1986 American Cancer Society Junior Faculty Clinical Fellowship
1976-1977 W. Barry Wood Student Research Fellowship, Johns Hopkins
1973 Phi Beta Kappa
1973 Phi Beta Kappa Science Medal for Undergraduate Research
1973 Jonas Salk Scholarship of the City University
1973 Summa cum laude, BS, City College

  1. Ross DW, Wanchoo R, Guigova A, Ghiuzeli C, Allen SL, Jhaveri KD. “Light chain Fanconi syndrome in a patient with acute myeloid leukemia and monoclonal gammopathy of undetermined significance.” CEN Case Reports DOI 10.1007/s13730-016-0232-3, 2016.
  2. Patten PEM, Ferrer G, Chen SS, Simone R, Marsilio S, Yan XJ, Gitto Z, Yuan C, Kolitz JE, Barrientos J, Allen SL, Rai KR, MacCarthy T, Chu CC, Chiorazzi N. “Chronic lymphocytic leukemia cells diversify and differentiate in vivo via a nonclassical TH1- dependent, Bcl-6- deficient process.” JCI Insight 1:e86288.doi:10.1172/jci.insight.86288, 2016.
  3. Oroszi G, Brody J, Yang T, Allen SL, Devoe C, Zhang X. “Sequential development of two separate therapy-related myeloid neoplasms following radiotherapy for prostate cancer.” Leukemia and Lymphoma  DOI:10.3109/10428194.2016.1154960.
  4. Cui X, Zhang L, Magli AR, Catera R, Yan X-J, Griffin DO, Rothstein TL, Barrientos J, Kolitz JE, Allen SL, Rai KR, Chiorazzi N, Chu CC. “Cytoplasmic myosin exposed apoptotic cells appear with caspase-3 activation and enhance CLL cell viability.” Leukemia  30: 74-85, 2016
  5. Dulmovits B, Appiah-Kubi AO,Papoin J, Hale J, He MM, Al Abed Y, Didier S, Gould M, Husain-Krautter, S, Sharon A, Chan KWH, Vlachos A, Allen SL, Taylor N, Marambaud P, An X, Gallagher PG, Mohandas N, Lipton J, Liu JM, Blanc L. “Pomalidomide reverses γ-globin silencing through the transcriptional reprogramming of adult hematopoietic progenitors.” Blood 127: 1481-92, 2016.
  6. Sherry B, Jain P, Chiu PY, Leung L, Allen SL, Kolitz JE, Rai KR, Barrientos J, Liang S, Hawtin R, Chiorazzi N. “Identification and characterization of distinct IL-17F expression patterns and signaling pathways in chronic lymphocytic leukemia and normal B lymphocytes.” Immunology Research  63: 216-27, 2015.

View more at PubMed